|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:psoriatic_arthritis
ankylosing spondylitis
plaque psoriasis
|
|
gptkbp:ATCCode
|
gptkb:L04AC13
|
|
gptkbp:CASNumber
|
1143503-33-7
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
gptkb:ixekizumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Taltz
|
|
gptkbp:indication
|
active psoriatic arthritis
moderate to severe plaque psoriasis
active ankylosing spondylitis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
IL-17A inhibitor
|
|
gptkbp:monoclonalAntibodyType
|
humanized
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (for some indications)
|
|
gptkbp:PubChem_CID
|
DB11575
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
injection site reactions
upper respiratory tract infections
tinea infections
|
|
gptkbp:target
|
gptkb:interleukin-17A
|
|
gptkbp:UNII
|
3ZWH8Q7W1N
|
|
gptkbp:bfsParent
|
gptkb:礼来公司
|
|
gptkbp:bfsLayer
|
5
|